Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

CellaVision, Audiocast, Q3'26

By Inderes10/29/2026, 10:00 AM
CellaVision

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Steve Ferguson
00:00 - 03:49

Welcome, everyone, and thank you for joining us on our call this morning. My name is Steve Ferguson and with me is our chief financial officer, Monica Johnson. And we appreciate you taking the time to join us as we present CellaVision's results for the third quarter of 2026. Following the presentation, we'll be happy to take your questions. Before I jump into the quarterly results, I'd like to take a moment to thank our employees, our customers, our partners, and our shareholders for their continued trust and commitment to CellaVision. It's through our combined efforts, bringing together innovation and strong commercial execution, that we continue to create long-term value and fulfill our mission, which is to advance laboratory workflow and diagnostic certainty through intelligent microscopy. And with that, let's turn to our performance for the third quarter. CellaVision's third quarter reflected really solid progress across the group. The quarter delivered an increase in net sales of 13.6%, and we reached 200 million SEK in the quarter. Sales increased organically by 13.4%, with only a minor currency effect. EBITDA amounted to 64 million SEK, which corresponds to a 32% EBITDA margin across the regions. Americas continued to build on the strong second quarter that we saw earlier this year. Sales were up 32% to 89 million. SEK, with the primary drivers being strong demand for large connected instrument platforms. And in this quarter, we saw a notable software contribution. Small instrument sales also continue to recover, which is a positive sign for the overall product mix. EMEA was down 10% compared to a very strong quarter last year. That said, the picture is much more balanced. Sales have sequentially progressed since quarter one. The key update from the region focuses on the Bone Marrow Aspirate application. Our most recent launch has progressed from customer evaluations to generating first revenue. With the initial installations in EMEA marking the beginning of customer adoption. APAC grew 91% organically with broad-based growth outside of China, driven by solid performance in both instruments and reagents. That is the picture here. The standout is Japan, where we're seeing notable momentum in converting the installed base to CellaVision reagents, which strengthens the recurring revenue stream going forward. The Bone Marrow Aspirate application has generated growing revenue in EMEA, and that's a meaningful milestone in our expansion. Expansion into specialized microscopy is progressing across the region, and we are seeing continued positive customer interest. On the regulatory side, the FDA 510(k) review is ongoing in the United States, and our aim is to obtain market clearance before the end of this year. On the development side, the Fourier Ptychographic Microscopy technology and our next-generation hematology analyzers are progressing through key phases towards a future market introduction. We see this technology platform as a significant step forward for digital cell morphology in hematology. It combines meaningfully higher image quality with substantially higher throughput compared to what is available today on the market. It also opens the door for CellaVision to adjacent fields such as pathology and cytology. Now, let me hand over to Monika, who will present us with an overview of the financial results for the quarter.

Monica Johnson
03:50 - 06:05

Thanks, Steve. So let's unpack the P&L and cash flow. Net sales were 200 million SEK in the quarter, representing 14% growth, or 13% organic growth, against the same quarter last year. It is also worth noting that the year-to-date organic growth is 4%, despite the weaker Q1. We had a gross margin of 66% in the quarter. That entails amortization of capitalized development expenditures for Bone Marrow Aspirate and the upgraded software program launched in Q1 of this year. We are amortizing 5 MSEK versus 2 MSEK last year. The gross margin was also negatively impacted by the sales mix. Operating expenses landed at 82 million SEK, equaling 41% of net sales. If we unpack that, we see that sales and marketing expenses are kept at stable levels. Administration expenses were impacted by costs of 4 million SEK associated with the final settlement of the CEO transition. R&D costs before capitalization were 39 million SEK, somewhat lower than last year, reflecting lower consultant and personnel costs during the summer vacation period compared to the same quarter last year. We have a higher capitalization of 16 million SEK, and that results in an R&D cost of 23 million SEK. The higher capitalization is mainly due to the fact that some projects have recently advanced into more mature phases. The EBITDA increased to 64 million SEK with an EBITDA margin of 32%. We are continuing to invest in R&D, representing 9% of net sales, and our R&D investment programs are developing well and maturing according to plan. Finally, operating cash flow was 68 million SEK. The higher sales and the reduced inventory contributed positively to the cash flow, which totaled 46 million SEK for the quarter. Our financial position remains robust, with cash and cash equivalents of 290 million SEK sitting on the balance sheet. Let's look into the regional highlights.

Steve Ferguson
06:06 - 10:48

Okay, at a regional level, thank you, Monika. At a regional level, the Americas continue to perform exceptionally strongly. Sales in the quarter were 89 million SEK, which is up 32%. And this has really been driven by demand for large connected platforms, as our platform has the flexibility to connect smaller and large laboratories, and demand for that as laboratories consolidate is really helping drive sales in that region. In this quarter, the most notable win was a significant tender in Canada, which has led to a large installation in that region. If we look at EMEA, sales were 86 million SEK, down from last year, but after the inventory correction in quarter one, we have now seen underlying growth represented through two consecutive quarters of growing sales. Interesting here, looking to the future. Bone Marrow Aspirate has started. As I mentioned earlier, evaluations are generating positive feedback. And that is leading to early adoption, which is leading to growth. And we expect sales in the quarter to represent 1% to 2% of the growth. Reagent growth continues to strengthen across EMEA. And this is positive for us because this is recurring revenue, and this is an important part of the combined value offering or value proposition of CellaVision. Both reagents and the microscopy combined give us a good platform and make us a more attractive proposition for laboratory customers. If we then look at APAC, we see really pleasing sales here with 90% growth in the quarter, all outside of China. This has been driven across the portfolios of both instruments and reagents, which are growing stronger. It is across the region, both in South Asia and East Asia. I do want to call out the Japan performance here, which was fantastic and really has been driven by a conversion to CellaVision reagents in the largest national laboratory chain there. So a very pleasing result when you look at it across the three regions. If we look briefly at sales by product group, instruments represented 105 million SEK in the quarter, up 14%. As I've said, driven by the larger platforms in the Americas, reagents were up 12% at 45 million. SEK. And again, this is pleasing for us. This is a region that we have focused on. And sales have positively developed there, in Asia, as I've mentioned, and in EMEA. And then finally, a word on software and spare parts sales. There are 49 million SEK. SEK were up 15%, again driven by increased software sales, again driven by the Americas. To summarize the key takeaways, the quarter resulted in net sales that are up 13.6%, as I've said, driven by 32% growth in the Americas. EMEA is 10% down on last year, representing a tough comparison. But quarter on quarter, we are seeing underlying growth on both the reagents and on the BMA Application platform and in APAC, really strong performance there driven by Japan. All of this is outside of China, and it is across both the reagents and the instrument platform. I just want to call out before we close today that the Power of Focus strategy was put in place to cover the five years up to 2025, and that strategy has delivered across multiple areas for us. And we have made commercial and regulatory progress with the Bone Marrow Aspirate and reached a meaningful milestone. That is our first significant launch in that period. Following quickly on that will be the development of the Fourier Ptychographic Microscopy technology. So our innovation pipeline is extremely strong. I would like to highlight to you that we plan to take you through the revised strategy. So we have a new strategy period, a new strategy focus, and we plan to launch that. To provide more insight into that, we will host our Capital Markets Day on February 17th next year in Stockholm. So a heads up for now to hold that date. Those are the final remarks today. So with that, I'll pause and hand over for any questions.

Operator
10:50 - 11:07

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Simon Larsson from Danske Bank. Please go ahead.

Simon Larsson
11:09 - 11:22

Yes, and good morning, Steve and Monika. My first question relates to the price increases that you mentioned in the report. Could you give us any hint of the magnitude of those, as that would be my first question.

Monica Johnson
11:24 - 11:41

Yes. So they came into place from Q2. But we really see the full effect now in Q3, and the magnitude is, more or less, I would say, very roughly following inflation.

Simon Larsson
11:43 - 12:13

Okay, good. I was also wondering about the gross margins, because obviously they contracted a bit here quarter-over-quarter. And you are mentioning, of course, amortization, but also a bit of a mix effect in this. So it would be super helpful if you could maybe split those two factors out and separate them so that we understand what is sort of the more long-term pressure on gross margin from the amortization and what could maybe be recouped when the mix improves?

Monica Johnson
12:15 - 12:56

Yeah. Great question. On the amortization, I would say that will stay on this level until we launch the next product. So you will be aware of that when we start launching, and you will see new effects on amortization. But until then, we expect to stay on this level. When it comes to sales mix, that is really due to the fact that within the quarters we see different mixes of small and large instruments, for example, as well as the total mix of reagents, software, and so on. So it's a natural swing between the quarters.

Steve Ferguson
12:58 - 13:08

Yeah, yeah. And that is because sales can vary quarter to quarter. Simon. That is something where there are no surprises. It is in line with the nature of the business.

Simon Larsson
13:10 - 13:26

Yes, indeed. But maybe to rephrase the question a bit. So, I think there is a 3 million increase in amortization. Do you know roughly how much of those 3 million ends up in the COGS line item? Just trying to back out the underlying gross margin.

Unknown 1
13:26 - 13:27

Oh, okay. Yeah. All of it.

Monica Johnson
13:27 - 13:28

That.

Simon Larsson
13:29 - 14:05

That 3 million moves into COGS. Yeah. Yeah. Okay. Very helpful. Lovely. Perfect. And then, I was also wondering about the larger tender in Canada that you mentioned. It is driving growth in the Americas region. Do you think it is possible to keep up this level of sales in the Americas going forward, or should we expect to see slower development now after two quite strong quarters? I am not asking for any percentage guidance, but rather looking at the absolute level. So is there anything to be mindful of looking at the Americas in the future here?

Steve Ferguson
14:06 - 14:38

We are still confident that the Americas is a growth case for us. The demand for connected laboratory solutions is high in those developed markets as the laboratory customers are looking for efficiencies and our solutions can provide them with that. We obviously are working with our partner there. There is a really strong and positive relationship. We have reasonable visibility into the future. So we still see opportunities for growth there in that region.

Simon Larsson
14:41 - 15:08

Good. The final one from my end would be on. You mentioned in the CEO letter, Steve, that there is continued pressure on healthcare investments in some markets. Would you mind breaking those markets out for us and providing more color on which markets you see headwinds in, and if we should expect that headwind to increase or decrease as you move into the final quarter of the year. Any color on that would be nice.

Steve Ferguson
15:09 - 15:46

Yeah. I think there are probably no surprises here that, globally, China is the market that is undergoing the most pressure. As government policy tries to drive cost out of the healthcare system. So that's probably the most notable one, then I think generally across Europe or EMEA, most of the Western governments are trying to get more value for money out of what they're investing there. So it is a headwind, but it is something we feel as though we can navigate positively. So we have the solutions in place to deal with that.

Simon Larsson
15:48 - 15:51

Okay. Very good. Thanks so much.

Monica Johnson
15:52 - 15:52

Thanks.

Steve Ferguson
15:53 - 15:53

Thanks, Simon.

Operator
15:55 - 16:00

The next question comes from Ludvig Lundgren from Arctic Securities. Please go ahead.

Ludvig Lundgren
16:02 - 16:33

Yes. Hi, everyone. Thank you for taking my questions. I wanted to start out on instrument sales in Europe. It was down against a quite tough comparison year-over-year. But it sounds like the demand trajectory is turning slightly more positive compared to H1. So, with the comparison base getting a bit easier, I believe in Q4. Would you say it's possible for this segment to return to growth this year? And also how should we think about the outlook into 2027?

Steve Ferguson
16:35 - 17:01

Yeah, I think that is the major takeaway. Thanks, Ludvig, for the question. I think this is clearly due to the inventory correction in Q1. There's clearly been a comparator from Q3 last year that may be slightly inflated. We expect the underlying business is robust. We expect that we have solutions there that are needed by our customers. So we expect that the instrument sales will continue to grow.

Ludvig Lundgren
17:04 - 17:34

Okay. Thanks. Very clear. I also wanted to jump over to reagents, as there is very strong growth here. I guess it was boosted by a few million from the delayed orders in France. But I think there is typically not that much seasonality in this business. So is it fair to expect a similar absolute sales level in Q4 for the group reagent sales?

Steve Ferguson
17:35 - 18:00

Yes, there is some seasonality there, but this is really a volume-driven part of the business. So as more tests are done, more reagents are consumed. So we grow in line with market volumes. And the nature of that business is recurring. So whether it's quarter on quarter or over a six-month period, that's the nature of our business. You can have fluctuations, but this is recurring revenue and we expect that to develop positively.

Ludvig Lundgren
18:02 - 18:11

Okay. And is there any seasonality difference between Q3 and Q4; is Q4 a bit slower in general, or how do you think about that difference?

Steve Ferguson
18:12 - 18:36

No, not particularly. I think if you look at the in vitro diagnostic industry, you do see seasonal variation or quarter-to-quarter fluctuations. I have said before that judging the performance of the company on a single quarter is a real challenge because it is a much more long-term oriented business than that. But we don't expect any particular trends in Q4 that would pose any surprises.

Ludvig Lundgren
18:37 - 19:09

Okay. Very clear. And then the final question from my side. On the R&D cost thinking now before capitalization. I believe this is down 10% versus the same period last year. And you highlighted that this is related to lower consulting costs and headcount. So, I believe this can also fluctuate a bit between quarters, but it sounds to me that the run rate of the R&D organization is down a bit versus last year. Is that a fair conclusion? Is it something we can extrapolate as well?

Monica Johnson
19:10 - 19:37

Yeah. So we have the impact here from the vacation period in Q3. But we also have an impact of which phase each and every project is in. So it is a natural fluctuation as well between the quarters that we see. I would still expect us to be more towards a 20-21% of sales level rather than the 19% that we are at today in Q3.

Ludvig Lundgren
19:38 - 19:54

Okay. Thanks. Okay. And just a final follow-up on that. So I see that the number of employees is still growing while OpEx is quite stable. Where are those additional employees going currently? To which item in the P&L does this relate?

Monica Johnson
19:56 - 20:10

The majority is still directed towards R&D in Lund. Where we are growing. But they are also in some places replacing consultants. So that is why you might not see that directly impacting OpEx.

Ludvig Lundgren
20:13 - 20:17

Okay. Thanks. Those were my questions. I will jump back into the queue. Thank you.

Operator
20:20 - 20:33

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Elvin Roeder from DNB Carnegie. Please go ahead.

Elvin Roeder
20:34 - 21:09

Uh, yes. Good morning, Steve and Stephen. Monica, I hope you can hear me. I have a couple of questions. Some are perhaps of a follow-up nature, but perhaps beginning in America, you obviously have very strong organic growth here again. Is it possible to quantify or split out the effect from the tender in Canada, and how much of the growth is coming from the replacement of an installed base versus new customers or installations?

Steve Ferguson
21:11 - 21:45

Yes, I think so. The short answer to that. Thank you for the question. The short answer there is that this is a mix across the portfolio. The tender win in Canada is a significant win. It is incremental for us. But there is a mix of instruments in there that will be refreshed as part of that. And we look at the installed base globally, and there are opportunities for refreshes and new business in equal measure there. So there is a real balance across the quarter in terms of new business wins and instrument refreshes there.

Elvin Roeder
21:49 - 22:21

Okay. Great. Thank you. And then, perhaps on APAC, obviously very strong growth here in Q3. And I hear what you say that you have a strong demand if we look beyond China, but should there be any timing effects in installations that we should have respect for here in Q3 when we look towards Q4 and Q1, or would you say that the pace of installation of instruments has been normal?

Steve Ferguson
22:23 - 23:06

Yeah. Nothing on timing effects that we are noting. The one thing I would say is that any quarter can fluctuate based on the timing of a tender. The timing of an install and the timing of qualification by the laboratories can have an impact. But I think looking longer term than any single quarter, we are really pleased with the development of the reagent business. We have won the business with one of the largest national laboratory testing centers in Japan, one of the largest chains there. And we expect that to be recurring over years, not just over a single quarter. So we think this is really stable and recurring revenue for us.

Monica Johnson
23:07 - 23:26

And maybe if I just add to that, one thing to have in mind is that in Q4 last year, we had some sales activity in China. While, as we have mentioned, we have very limited sales. Now, the next quarter comparison in APAC will be a little tougher versus this quarter. Compared to the periods where there were no sales in China last year either.

Elvin Roeder
23:28 - 23:58

Mhm. Very clear. Thank you. And then just the final one from my end, perhaps a bit tied to Jen's part. Is it possible to describe what has been driving adoption in APAC as you are seeing it now; is it more that there are a lot of tenders coming live that you have been strongly positioned in? Or is there anything particularly that you have done within the product portfolio that is causing this to kind of take off now? Is it possible to comment on that?

Steve Ferguson
23:59 - 24:48

Yeah, I think, you know, to put it not to oversimplify it, but this is actually a result of sustained focus on that part of the business in that region. The team has worked in a dedicated fashion, particularly in Japan and other major markets in that region, to really promote and ensure that customers are clear on the value proposition of combining our microscopy solution and our reagent solution. And customers benefit from both of those together. So it's really a commercial execution topic. It is a positive in the sense that there are opportunities. This is an example. Now for us, we can take that as a model and start to look at where is the next region that we could replicate that in? But it is really down to commercial focus and strong execution there.

Elvin Roeder
24:50 - 24:53

Okay, great. Thank you so much. I will get back in line.

Monica Johnson
24:55 - 24:55

Thank you.

Steve Ferguson
24:56 - 24:56

Thank you. Evan.

Operator
24:57 - 25:04

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Steve Ferguson
25:06 - 26:28

Yes. Thank you, everyone, for joining us this morning. Once again, a really solid quarter. Very pleasing to be part of this. It is my first full quarter with the company. And I just want before we close to call out our employees in particular for the way they have responded to the new leadership. I am grateful for the work that they have done previously, which has actually driven the results in this quarter. So, I just want to call out the team and thank them sincerely for all their hard work and all their efforts and for the way that they've embraced the change, but also for their focus in sustaining the business through another successful quarter. In terms of the financial calendar, our year-end bulletin will be published on February 4th. I look forward to commenting on that report. I will then take your questions. I would like to remind you to save the date for the Capital Markets Day event on February 17th next year in Stockholm, and we will present our updated strategic direction and our priorities between now and 2030. We will hopefully be able to give you a greater level of granularity and more insight into the exciting prospects we have when it comes to our innovation pipeline. So with that, I will close the call today. Thank you for joining and have a great day. Thank you, Monica.

Monica Johnson
26:29 - 26:29

Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…